A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0268-0965 in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 13 Sep 2022
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
Most Recent Events
- 28 Aug 2020 Status changed from recruiting to completed.
- 24 Apr 2020 Planned End Date changed from 28 Aug 2020 to 28 Jul 2020.
- 24 Apr 2020 Planned primary completion date changed from 28 Aug 2020 to 28 Jul 2020.